The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 342:1294-1295 April 27, 2000 Number 17
NextNext

Epoetin for Severe Anemia in Hepatoerythropoietic Porphyria

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Hepatoerythropoietic porphyria is a rare autosomal recessive disorder of heme biosynthesis caused by a deficiency of uroporphyrinogen decarboxylase. Excessive accumulation of photoactive porphyrins in the skin, bone marrow, and peripheral blood results in photodermatitis, secondary skin infections, and "intractable" anemia.1 We report the successful treatment of life-threatening anemia with recombinant human erythropoietin (epoetin) in a patient with late-onset hepatoerythropoietic porphyria.

A 68-year-old white man (Karnofsky score, 20)2 with a 36-year history of porphyria and anemia was admitted for severe heart failure (left ventricular ejection fraction, 30 percent). Disfiguring scarring with inflamed erosions was present on sites exposed . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.